MEI Pharma To Host Annual Meeting Of Stockholders

              MEI Pharma To Host Annual Meeting Of Stockholders

Live Webcast from New Orleans on Thursday, December 5th

PR Newswire

SAN DIEGO, Nov. 26, 2013

SAN DIEGO, Nov. 26, 2013 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Central
time on Thursday, December 5, 2013 at the W New Orleans, 333 Poydras Street,
New Orleans, LA 70130, to consider and vote on certain matters, including the
election of three directors, the ratification of the appointment of the
Company's independent registered public accounting firm and approval, on an
advisory basis, of the compensation of the Company's named executive officers.
A live webcast of the meeting will be accessible at
www.meipharma.com/investor. A replay will be available approximately one hour
after the presentation.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor
being developed for advanced hematologic diseases, such as myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML). The Company initiated a
randomized, placebo-controlled Phase II trial of Pracinostat in combination
with Vidaza (azacitidine) in patients with previously untreated MDS in June
2013. An open-label Phase II trial of Pracinostat in combination with Vidaza
in elderly patients with AML who are unsuitable for intensive chemotherapy is
open for enrollment. MEI Pharma is also developing ME-344, a mitochondrial
inhibitor derived from its isoflavone-based technology platform. Results from
a first-in-human, single-agent clinical study of ME-344 in patients with
refractory solid tumors were presented in October 2013. In September 2013, the
Company further expanded its pipeline of drug candidates with the acquisition
of PWT143, a highly selective PI3-kinase delta inhibitor. For more
information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.marshalledwardsinc.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, (858) 792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.